Tracking the Real-Life impact of new Alzheimer's drug

This study aims to create a registry to understand how the recently approved Alzheimer's drug lecanemab affects patients and their caregivers in everyday life. Researchers will enroll 20 Alzheimer's patients receiving lecanemab infusions and their caregivers to collect data on their experiences over time. The goal is to gather real-world information about treatment effects, quality of life, and caregiver burden that isn't typically captured in clinical settings.